Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 29;22(23):12920.
doi: 10.3390/ijms222312920.

Nutraceutical Approach to Chronic Osteoarthritis: From Molecular Research to Clinical Evidence

Alessandro Colletti  1   2 , Arrigo F G Cicero  2   3
Affiliations
Review

Nutraceutical Approach to Chronic Osteoarthritis: From Molecular Research to Clinical Evidence

Alessandro Colletti et al. Int J Mol Sci. .

Abstract

Osteoarthritis (OA) is a degenerative inflammatory condition of the joint cartilage that currently affects approximately 58 million adults in the world. It is characterized by pain, stiffness, and a reduced range of motion with regard to the arthritic joints. These symptoms can cause in the long term a greater risk of overweight/obesity, diabetes mellitus, and falls and fractures. Although the current guidelines for the treatment of OA suggest, as the gold standard for this condition, pharmacological treatment characterized by non-steroidal anti-inflammatory drugs (NSAID), opioids, and cyclooxygenase (COX)-2-specific drugs, a great interest has been applied to nutraceutical supplements, which include a heterogeneous class of molecules with great potential to reduce inflammation, oxidative stress, pain, and joint stiffness and improve cartilage formation. The purpose of this review is to describe the potential application of nutraceuticals in OA, highlighting its molecular mechanisms of actions and data of efficacy and safety (when available).

Keywords: chondroitin; collagen; glucosamine; hyaluronic acid; methylsulfonylmethane; nutraceuticals; osteoarthritis; vitamin C; vitamin D.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Hootman J.M., Helmick C.G., Barbour K.E., Theis K.A., Boring M.A. Updated projected prevalence of self-reported doctor-diagnosed arthritis and arthritis-attributable activity limitation among us adults, 2015–2040. Arthritis Rheumatol. 2016;68:1582–1587. doi: 10.1002/art.39692. - DOI - PMC - PubMed
    1. Szychlinska M.A., Trovato F.M., Di Rosa M., Malaguarnera L., Puzzo L., Leonardi R., Castrogiovanni P., Musumeci G. Co-expression and co-localization of cartilage glycoproteins CHI3L1 and lubricin in osteoarthritic cartilage: Morphological, immunohistochemical and gene expression profiles. Int. J. Mol. Sci. 2016;17:359. doi: 10.3390/ijms17030359. - DOI - PMC - PubMed
    1. Aiello F.C., Trovato F.M., Szychlinska M.A., Imbesi R., Castrogiovanni P., Loreto C., Musumeci G. Molecular links between diabetes and osteoarthritis: The role of physical activity. Curr. Diabetes Rev. 2017;13:50–58. doi: 10.2174/1573399812666151123104352. - DOI - PubMed
    1. Fajardo M., Di Cesare P.E. Disease-modifying therapies for osteoarthritis. Drugs Aging. 2005;22:141–161. doi: 10.2165/00002512-200522020-00005. - DOI - PubMed
    1. Sengupta K., Alluri K.V., Satish A.R., Mishra S., Golakoti T., Sarma K.V., Dey D., Raychaudhuri S.P. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res. Ther. 2008;10:R85. doi: 10.1186/ar2461. - DOI - PMC - PubMed